Halozyme Therapeutics

Valuation Analysis

About the Company

Halozyme Therapeutics en bref

Halozyme Therapeutics (HALO) is currently trading at 59,76 € with a market capitalization of 7,1 Md €. The trailing P/E ratio stands at 24.05x, with a forward P/E of 6.93x. The 52-week range spans from 44,51 € to 71,68 €; the current price is 16.6% below the yearly high. Year-over-year revenue growth stands at +42.2%. The net profit margin stands at 23.13%.

💰 Dividende

Halozyme Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent Halozyme Therapeutics (HALO) au consensus : Acheter. L'objectif de cours moyen est de 73,14 €, soit un potentiel de +22.39% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 49,69 € à 83,69 €.

Halozyme Therapeutics : la thèse d'investissement en détail

Halozyme Therapeutics (HALO) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 42.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 76.67%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 99.4% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

The debt-to-equity ratio of 991.21% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn. Short interest sits at 14.88% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The forward P/E of 6.93x is meaningfully below the trailing 24.05x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 22.39% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (14.88%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Halozyme Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.